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Abstract
Background: FeCo/graphitic-carbon nanocrystals (FeCo/GC) are biocompatible, high-relaxivity, multi-functional nanopar-
ticles. Macrophages represent important cellular imaging targets for assessing vascular inflammation. We evaluated FeCo/
GC for vascular macrophage uptake and imaging in vivo using fluorescence and MRI.
Methods and Results: Hyperlipidemic and diabetic mice underwent carotid ligation to produce a macrophage-rich vascular
lesion. In situ and ex vivo fluorescence imaging were performed at 48 hours after intravenous injection of FeCo/GC
conjugated to Cy5.5 (n=8, 8 nmol of Cy5.5/mouse). Significant fluorescence signal from FeCo/GC-Cy5.5 was present in the
ligated left carotid arteries, but not in the control (non-ligated) right carotid arteries or sham-operated carotid arteries
(p=0.03 for ligated vs. non-ligated). Serial in vivo 3T MRI was performed at 48 and 72 hours after intravenous FeCo/GC
(n=6, 270 mg Fe/mouse). Significant T2* signal loss from FeCo/GC was seen in ligated left carotid arteries, not in non-ligated
controls (p=0.03). Immunofluorescence staining showed colocalization of FeCo/GC and macrophages in ligated carotid
arteries.
Conclusions: FeCo/GC accumulates in vascular macrophages in vivo, allowing fluorescence and MR imaging. This multi-
functional high-relaxivity nanoparticle platform provides a promising approach for cellular imaging of vascular
inflammation.
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Introduction
Inflammation is a major contributor to atherosclerosis, a leading
cause of death worldwide [1–3]. Macrophages in the vessel wall
have been associated with atherosclerotic plaque rupture and
acute myocardial infarction [4–7]. Thus, imaging of vascular
macrophages may be useful for characterizing plaque biological
activity.
Cellular and molecular imaging of atherosclerosis and vascular
inflammation has made significant progress, but remains chal-
lenging [8–22]. FeCo/graphitic-carbon nanocrystals (FeCo/GC)
are composed of an iron-cobalt (FeCo) core with a graphitic-
carbon shell [23]. We have shown that the FeCo core provides
higher relaxivity for MRI compared to other commercially
available contrast agents, while the graphite shell enables
biocompatibility and high optical absorbance in the near-infrared
region for potential thermal therapy [23]. We have also shown the
potential of FeCo/GC for stem cell imaging in vitro as well as high-
resolution vascular angiography in vivo [23,24], but in vivo cellular
imaging of FeCo/GC has not been studied.
The aim of the current study was to investigate FeCo/GC for in
vivo macrophage uptake and imaging in a murine model of
vascular inflammation. We show carotid artery macrophages take
up FeCo/GC and can be imaged by in situ fluorescence and in vivo
high-field MRI.
Results
Fluorescence imaging of carotid arteries after
administration of FeCo/GC
Both in situ and ex vivo fluorescence imaging at 48 hours showed
high signal from the ligated left carotid arteries, confirming FeCo/
GC uptake in the vascular lesions (Figure 1A; yellow arrows). In
contrast, there was no significant FeCo/GC accumulation seen in
the non-ligated right carotid arteries (Figure 1A, red arrows).
Furthermore, sham operated mice did not show significant signal
in either left or right carotid arteries (Figure 1B).
Quantitative analysis of both in situ and ex vivo signal intensities
showed that the ligated left carotid arteries had significantly higher
fluorescence than the control (non-ligated) right carotid arteries
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vivo(left vs. right): 59.2617.2 vs. 0.360.3,p=0.03). Also,theligated
left carotids had significantly higher fluorescence than sham left
carotids (in situ (ligated vs. sham): 2.360.4 vs. 0.960.1, p=0.046, ex
vivo (ligated vs. sham): 59.2617.2 vs. 0.360.3, p=0.046).
In vivo MRI of carotid arteries after administration of
FeCo/GC
MRI prior to FeCo/GC administration (Figure 2A-Pre) showed
that the ligated left carotid artery (yellow arrow), as expected, was
smaller than the non-ligated right carotid artery (red arrow). Post
FeCo/GC injection, serial MRI showed reduction in left carotid
lumen area due to T2* signal loss from FeCo/GC accumulation at
both 48 and 72 hours. In contrast, luminal area reduction due to
T2* signal loss was not seen in the control (non-ligated) right
carotid arteries (Figure 2A).
The measured % reduction of carotid lumen area at 48 and
72 hours for the ligated left carotid arteries was significantly greater
than for the non-ligated controls, indicating the accumulation of
FeCo/GC in the carotid lesion (Figure 2B; 48 hours (left vs. right):
60.1610.7% vs. 16.969.9%, p=0.03; 72 hours (left vs. right):
83.964.6% vs. 21.367.2%, p=0.03). Furthermore, preliminary
testing (n=3) of an eight-fold lower FeCo/GC dose at higher field
strength (7T) also showed T2*-induced lumen reduction in ligated
left vs. right carotid arteries (28.065.7% vs. 25.5661.2%, p=0.1).
Histology
Immunohistochemistry for macrophages demonstrated that
there was substantial macrophage infiltration in the neointima of
ligated left carotid arteries, accounting for 18.961.9% of the
neointimal area (Figure 3A,C). There was also significant smooth
muscle cell proliferation, accounting for 34.563.7% of the
neointimal area (Figure 3B,C). Furthermore, carotid immunoflu-
orescence staining showed that FeCo/GC colocalized with
macrophages (Figure 3D). The specificity of FeCo/GC for
macrophages was further confirmed by immunofluorescence
staining showing abundant uptake in the macrophage-rich liver
and scant uptake in the macrophage-poor heart (Figure 3E,F).
Discussion
In an experimental model of vascular inflammation, we have
shown that a FeCo-based, graphite-coated nanoparticle can
accumulate in vivo in vascular macrophages and can be imaged by
fluorescence and MRI. To the best of our knowledge, this study is
the first to show the use of FeCo or graphite-coated nanoparticles
for in vivo macrophage imaging. We have previously reported that
FeCo/GC exhibited higher T1 and T2 relaxivities than commer-
cially available iron-oxide- and gadolinium-based contrast agents,
with cell hyperthermia capabilities, and without evidence of in vitro
or in vivo toxicity [23,24]. Furthermore, we have shown that FeCo/
GC has a long circulation time and can allow very high-resolution
MR angiography (down to 100 mm) [24]. By demonstrating in vivo
vascular macrophage uptake and imaging, we show that the potent
MRI characteristics and potential therapeutic capabilities of FeCo/
GC can be applied more broadly to atherosclerosis diagnosis and
therapy – from high-resolution angiography to detection of vascular
inflammation to macrophage thermal ablation.
Figure 1. Fluorescence imaging of FeCo/GC in mouse carotid arteries. (A) Both in situ and ex vivo images at 48 hours after FeCo/GC-Cy5.5
injection showed enhanced fluorescence signal localized to the ligated left carotid artery (yellow arrows), but not to the contralateral non-ligated
right carotid (red arrows). (B) Sham-operated mice showed no significant signal in either the left or right carotid arteries. (C) Quantitative analysis of
both in situ and ex vivo fluorescence signal intensity showed significantly greater fluorescence from ligated left carotid arteries compared to non-
ligated right carotid arteries. {p=0.03 vs. right carotid, *p=0.046 vs. sham left carotid.
doi:10.1371/journal.pone.0014523.g001
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modalities, including optical, nuclear, x-ray computed tomogra-
phy, and MRI [8–22]. Prior optical studies have used biolumi-
nescence, magneto-optical particles, or enzymatically activated
near-infrared agents [8,12,14,17,21]. MRI studies have primarily
used ultra-small superparamagnetic iron-oxide agents for detecting
macrophage infiltration in vascular lesions in both experimental
and clinical studies [15–17,22] Gadolinium-based micelles and
lipoproteins have also been used for macrophage MRI [9,19]. One
study used a combined carbon nanotube/iron-oxide complex for
macrophage cell imaging in vitro [20].
In addition to the advantageous MRI properties of FeCo/GC
discussed above, FeCo/GC can be conjugated with targeting
ligands or therapeutic drugs. We have also shown that the graphite
shell provides high optical absorbance for photothermal therapy
[23], while the FeCo component has the potential for magnetic
hyperthermia [25]. Thus, FeCo/GC nanoparticles have a wide
range of imaging, targeting, and therapeutic capabilities and
warrant further study.
While the carotid ligation model is advantageous in providing a
discrete, macrophage-rich vascular lesion, it cannot replicate the
complex, chronic plaques that develop in humans. Fluorescence
imaging required in situ carotid exposure due to limitations in
fluorescence tissue penetration. Fully noninvasive fluorescence
imaging may be enabled with alternative techniques, such as
fluorescence molecular tomography [8,14]. The MRI approach is
likely made more challenging by using a carotid ligation model, as
the ligation decreases both lumen size and flow. Aortic imaging in
a transgenic hyperlipidemic mouse model is an alternative [8].
Finally, while preliminary studies have shown no acute or chronic
toxicity of FeCo/GC [24], more extensive, large-animal toxicity
studies are needed prior to clinical translation.
In conclusion, the present study provides evidence that FeCo/
GC nanoparticles are promising multi-modality contrast agents for
vascular macrophage imaging. Further studies of this multi-
functional nanomaterial may enable improved imaging, and
therapy, of vascular inflammation in patients.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Administrative Panel on Laboratory
Animal Care at Stanford University (Assurance # A3213-01). All
procedures were performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Animals
A macrophage-rich murine carotid ligation model was used
[21,22]. Eight-week-old male FVB mice (n=17) were fed high fat
diet containing 40% kcal fat, 1.25% (by weight) cholesterol and
0.5% (by weight) sodium cholate (D12109, Research Diets, Inc.
New Brunswick, NJ, USA) [26]. After 1 month on the diet,
diabetes was induced by 5 daily intraperitoneal injections of
streptozotocin (STZ, 40 mg/kg, Sigma-Aldrich, Saint Louis, MO,
USA) dissolved in a citrate buffer (pH 4.5, Sigma-Aldrich, USA)
Figure 2. Serial in vivo MRI of carotid arteries with FeCo/GC. (A) The ligated left carotid artery (yellow arrow), as expected, was smaller than
the non-ligated right carotid artery (red arrow) prior to FeCo/GC injection (Pre). After FeCo/GC injection, T2* signal loss of the ligated left carotid
artery was seen at 48 and 72 hours. Luminal area reduction was not seen in the control (non-ligated) right carotid artery. (B) Quantitative analysis
showed significant % reduction in lumen area of ligated left vs. non-ligated right carotid arteries. {p=0.03 vs. Pre, *p=0.03 vs. right carotid.
doi:10.1371/journal.pone.0014523.g002
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from tail vein blood using a glucometer. If the glucose level was
below 200 mg/dL, animals were injected with STZ for 3
additional days. Two weeks after the initiation of STZ injection,
the left common carotid artery was ligated below the bifurcation
with the use of 5-0 silk ligature (Ethicon) under 2% inhaled
isoflurane [28]. Sham operation was performed by passing the
suture under the left carotid artery without constricting the artery.
The wound was closed by suture and the animals were allowed to
recover on a warming blanket.
FeCo/GC synthesis
The 7 nm FeCo/GC were synthesized as previously described
[23,24], then sonicated with 1 mg/mL phospholipid-polyethylene
glycol (PL-PEG) in water for one hour. To obtain singly suspended
FeCo/GC, the solution was centrifuged for 6 hours at 24,0006g.
Excess PL-PEG was removed by filtration and UV-vis was used to
determine nanocrystal and metal concentration.
For fluorescence imaging experiments the PL-PEG used was
DSPE-PEG5000-NH2 (NOF corp.). For fluorescent dye attach-
ment, Cy5.5-NHS ester was mixed with FeCo/GCPL-PEG-NH2
in phosphate buffered saline. Dye that was not attached to the
nanocrystal was removed by filtration. Samples prepared for in vivo
MRI imaging at 3 T were functionalized using DSPE-mPEG5000
(1,2-distearoyl-sn-glycero-3-phosphoethanolamine–N-[methoxy(-
polyethylene glycol)5000], Laysan Bio).
In vivo uptake and fluorescence imaging
To verify in vivo uptake of Fe/Co-GC in the carotid
macrophages, Cy5.5 was conjugated to FeCo/GC, allowing
fluorescence imaging and microscopy. FeCo/GC-Cy5.5 (8 nmol
of Cy5.5/mouse; 32.14 mg Fe/mouse) was injected intravenously
via tail vein into mice two weeks after carotid ligation (n=6) or
sham operation (n=2). These mice were imaged at 48 hours using
the Maestro
TM in-vivo imaging system (Cri, Woburn, MA). Under
inhalational anesthesia (2% isoflurane), left and right carotid
arteries were surgically exposed and in situ florescence imaging was
performed. Then, the carotid arteries were carefully removed en
bloc followed by ex vivo fluorescence imaging and immunohisto-
chemistry (see below).
In vivo MRI
To study noninvasive imaging of FeCo/GC by MRI, ligated
mice (n=6) were injected with FeCo/GC (270 mg Fe/mouse) and
imaged serially at 48 and 72 hours on a whole-body 3T MRI
Figure 3. Immunostaining of macrophages and FeCo/GC. (A) Immunohistochemical staining showed macrophages (by anti-Mac3 antibody)
infiltrating the neointima of the ligated left carotid artery. (B) Immunohistochemical staining for smooth muscle cells (by anti-SMA antibody). (C)
Quantitative analysis of proportion of neointima composed of macrophages and smooth muscle cells. (D) Immunofluorescent staining demonstrated
macrophages (green), FeCo/GC-Cy5.5 (red), nuclei (blue), and combined staining with strong colocalization (yellow), particularly near the luminal
border (arrow). (E) Immunofluorescent staining of the macrophage-rich liver also demonstrated strong colocalization (yellow) of FeCo/GC and
macrophages. (F) By contrast, the macrophage-poor heart tissue showed scant FeCo/GC uptake, with the few spots of uptake colocalizing with
macrophages (arrows).
doi:10.1371/journal.pone.0014523.g003
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gradient system and a custom 3 cm surface radiofrequency coil.
Another group of mice (n=3) were injected with an 8-fold lower
dose of FeCo/GC (32 mg Fe/mouse) and imaged at 48 hours on a
small-bore 7T system (30 cm bore magnet, Varian Inc. plus GE
‘‘Micro-Signa’’ environment), with a 9 cm gradient insert
(770mT/m, and 2500T/m/s, Resonance Research, Inc.) and a
custom 6-cm RF coil. To detect the T2* effects of FeCo/GC,
bright-blood images were acquired using gradient echo sequences
(3T: repetition time (TR) =100 ms, echo time (TE) =10 ms,
matrix size =2566256, slice thickness =1.0 mm, field of view
(FOV) =3 cm, flip angle =60u; 7T: same parameters except TR/
TE =50 ms/4.2 ms, slice thickness =0.5 mm). The slice position
was matched using the aortic arch as a reference point.
Image analysis
For in situ carotid fluorescence imaging, regions-of-interest
(ROIs) were placed on the left and right carotid regions and
trachea. Average signal intensity divided by exposure time for left
and right carotids was calculated and normalized to the trachea
signal. For ex vivo carotid imaging, ROIs were placed around the
entire left or right carotid artery and total signal intensity divided
by exposure time was calculated. For in vivo MRI, FeCo/GC
accumulation was assessed by measuring the extent of T2*-
induced reduction in carotid lumen size, which was calculated as
follows: % reduction of carotid lumen area = (1-[post-contrast
carotid lumen area]/[pre-contrast carotid lumen area]) x 100%
[15].
Histology
After euthanasia, carotid arteries were cut into two 3 mm
sections. These sections, as well as liver and heart, were embedded
immediately in optimum cutting temperature (OCT) compound
(Sakura Finetek USA, Inc., Torrance, CA) and flash frozen in liquid
nitrogen. Frozen sections (5 mm) were fixed in acetone for 10
minutes at 4uC [29]. After sections were washed in PBS, they were
incubated with anti-mouse Mac-3 antibody (BD Biosciences, San
Jose, CA) or anti-mouse alpha smooth muscle actin antibody
(AbcamInc., Cambridge,MA)overnight at4uC.Sections were then
incubated with biotinylated secondary antibodies at room temper-
ature for 30 minutes. Antigen-antibody conjugates were detected
with avidin-biotin-horseradish peroxidase complex (Vector Labo-
ratories, Burlingame, CA) according to the manufacturer’s
instructions. 3-amino-9-ethylcarbazole was used as chromogen.
Sections were counterstained with hematoxylin.
Immunofluorescence double staining with confocal microscopy
(Zeiss LSM 510, Carl Zeiss AG, Oberkochen, Germany) was
performed to examine colocalization of FeCo/GC-Cy5.5 and
macrophages. After incubation with anti-mouse Mac-3 antibody
overnight at 4uC, sections were stained with Alexa Fluor 488-
conjugated anti-rat IgG (Molecular Probes, Eugene, OR) at room
temperature for 2 hours. Finally, sections were stained with DAPI
(Sigma-Aldrich) to visualize cell nuclei.
Statistical analysis
All data are expressed as mean6SEM (standard error of the
mean). Comparisons of fluorescence and MRI measures between
left (ligated) and right (non-ligated) carotid arteries and between
timepoints were analyzed by the Wilcoxon signed-rank test.
Comparisons between ligated and sham left carotid arteries were
analyzed by the Mann-Whitney U test. P,0.05 was considered
statistically significant.
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